Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)

• Published in: Heart and vessels 2016-10, Vol.31 (10), p.1583-1589
• Main Authors: Shimomura, Mitsuhiro, Oyama, Jun-ichi, Takeuchi, Masayoshi, Shibata, Yoshisato, Yamamoto, Yusuke, Kawasaki, Tomohiro, Komoda, Hiroshi, Kodama, Kazuhisa, Sakuma, Masashi, Toyoda, Shigeru, Inoue, Yohei, Mine, Daigo, Natsuaki, Masahiro, Komatsu, Aiko, Hikichi, Yutaka, Yamagishi, Sho-ichi, Inoue, Teruo, Node, Koichi
• Format: Article
• Language: English
• Subjects: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Angiopoietin-like Proteins; Angiopoietins - blood; Atorvastatin Calcium - administration & dosage; Biomedical Engineering and Bioengineering; Cardiac Surgery; Cardiology; Clinical outcomes; Drug therapy; Female; Glycation End Products, Advanced - blood; Heart attacks; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Inflammation; Japan; Male; Medicine; Medicine & Public Health; Middle Aged; Myocardial Infarction - therapy; Original Article; Oxidative stress; Oxidative Stress - drug effects; Prospective Studies; Statins; Treatment Outcome; Vascular Surgery; Ventricular Function, Left - drug effects
• ISSN: 0910-8327; 1615-2573
• DOI: 10.1007/s00380-015-0773-y

Experimental ischemia–reperfusion models have shown that 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, statins, have cardioprotective effects. SAMIT (Statin Acute Myocardial Infarction Trial) is a multicenter prospective open randomized trial, designed to evaluate the effects of statin treatment from the earliest stage on cardioprotection in patients with acute myocardial infarction (AMI). Patients were randomly assigned to receive atorvastatin (initial dose of 40 mg at admission followed by the maintenance dose of 10 mg/day for 30 days) or not (control), and then immediately underwent percutaneous coronary intervention (PCI) for the culprit lesion. The primary endpoints were infarct size and left ventricular function. The secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and various biomarkers. There were no significant differences in baseline characteristics between 2 groups of the statin treatment group and the control group. The left ventricular ejection fraction increased at 6 months after the onset of AMI, compared with the baseline level in the atorvastatin group ( P